TY  - JOUR
AU  - Rossello, Xavier
AU  - Piñero, Antonio
AU  - Fernandez-Jimenez, Rodrigo
AU  - Sanchez-Gonzalez, Javier
AU  - Pizarro, Gonzalo
AU  - Galan-Arriola, Carlos
AU  - Lobo-Gonzalez, Manuel
AU  - Vilchez, Jean Paul
AU  - Garcia-Prieto, Jaime
AU  - Garcia-Ruiz, Jose M
AU  - Garcia-Alvarez, Ana
AU  - Sanz-Rosa, David
AU  - Ibáñez, Borja
PY  - 2018
DO  - 10.1007/s12265-018-9819-8
SN  - 1937-5387
UR  - http://hdl.handle.net/20.500.12105/9506
AB  - The administration of the selective β3 adrenergic receptor (β3AR) agonist BRL-37344 protects from myocardial ischemia/reperfusion injury (IRI), although the lack of clinical approval limits its translatability. We tested the cardioprotective effect of...
LA  - eng
PB  - Springer
KW  - Acute myocardial infarction
KW  - Cardioprotection
KW  - Ischemia/reperfusion injury
KW  - Mirabegron
KW  - Translational models
KW  - β3 adrenergic receptor
KW  - Acetanilides
KW  - Adrenergic beta-3 Receptor Agonists
KW  - Animals
KW  - Disease Models, Animal
KW  - Magnetic Resonance Imaging, Cine
KW  - Male
KW  - Myocardial Infarction
KW  - Myocardial Reperfusion Injury
KW  - Myocardium
KW  - Random Allocation
KW  - Swine
KW  - Thiazoles
KW  - Ventricular Function, Left
KW  - Ventricular Remodeling
TI  - Mirabegron, a Clinically Approved β3 Adrenergic Receptor Agonist, Does Not Reduce Infarct Size in a Swine Model of Reperfused Myocardial Infarction
TY  - journal article
ER  -